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November 1980 her plasma urea concentration was 60-2 mmol/l
(362 mg/lO0 ml) and she had peripheral gangrene in both feet. She
died on 1 December.
Postmortem examination showed a laminated haematoma 12 cm
in diameter around the left kidney, almost certainly due to the renal
biopsy. Histologically there were classical Kimmelstiel-Wilson nodules
and 60°,' hyalinised glomeruli in both kidneys, together with wide-
spread arteriosclerosis. The anterior lobe of the pituitary gland showed
old, extensive infarction.
Discussion
This patient had unequivocally diabetic hyperglycaemia
only at the time of treatment of her loin carbuncle. No record of
the retinal appearance was made then, but she had heavy
proteinuria and a reduced creatinine clearance, almost certainly
due to diabetic nephropathy. Quite possibly a long period of
asymptomatic hyperglycaemia had preceded formation of the
abscess. The return of normoglycaemia almost immediately
postoperatively suggests, however, that such hyperglycaemia
was probably mild, unless the pituitary infarction occurred at
about the same time. The extent of infarction must have been
incomplete physiologically, for despite low plasma growth
hormone concentrations plasma cortisol concentrations were
normal when measured seven months later. Pituitary infarction
has been reported in 2%,, of diabetics coming to postmortem
examination,3 and it was the regression of severe diabetic
retinopathy in a diabetic who developed Sheehan's syndrome4
that led to the use of hypophysectomy as a treatment for this
complication. Diabetic nephropathy was unaffected or worsened:
the original patient died in renal failure.4 Our patient's retino-
pathy did not regress despite pituitary hypofunction, and renal
function deteriorated relentlessly. Insulin requirements in
patients who had undergone hypophysectomy dropped to be-
tween one third and one quarter of their preoperative dosage,'
illustrating the Houssay phenomenon'; our case suggests that
in non-insulin dependent diabetics glucose tolerance may return
to normal, resembling the metabolic improvement seen in
patients with acromegaly who receive treatment.
It is now widely accepted that the development of diabetic
microvascular complications is proportional to the severity and
the duration of hyperglycaemia, although patients presenting in
renal failure with biopsy appearances of diabetic glomerulosclero-
sis and normal glucose tolerance have been reported.5 None of
these patients had retinopathy, and no data on pituitary function
were reported. Occult pituitary hypofunction may possibly be
present in such cases, and this would explain the apparent
paradox of severe diabetic microangiopathy in the presence of
normal glucose tolerance at the time of presentation.
RWB was supported by grant No I-AM-92200 from the National
Institutes of Health, Bethesda, Maryland, USA.
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Effects of pirbuterol and sodium nitroprusside on
pulmonary haemodynamics in hypoxic cor pulmonale
W MAcNEE, C G WATHEN, W J HANNAN, D C FLENLEY, A L MUIR
Abstract
The acute haemodynamic effects of oral pirbuterol (a
beta-agonist) were contrasted with those of sodium
nitroprusside, a vasodilator, in six patients with hypoxic
chronic bronchitis and emphysema. Sodium nitro-
prusside (1-5 mg/kg intravenously) reduced mean
pulmonary arterial pressure and total pulmonary
vascular resistance significantly (p <0-01) without change
in cardiac output or right ventricular ejection fraction,
measured by radionuclide ventriculography. Oral pir-
buterol (22 5mg) produced a greater reduction in total
pulmonary vascular resistance than sodium nitroprus-
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side, largely as a result of increasing cardiac output.
Right ventricular ejection fraction also increased signi-
ficantly after pirbuterol (p <0 01). Pirbuterol in a lower
dosage (15 mg by mouth) in six further patients with
hypoxic chronic bronchitis and emphysema produced
similar changes in total pulmonary vascular resistance
and right ventricular ejection fraction. Nine of the
patients who were studied acutely thereafter received
pirbuterol 15 mg thrice daily for six weeks, which
produced a significant fall in systolic pulmonary arterial
pressure and a rise in right ventricular ejection fraction
(p <0 01), without a significant fall in arterial oxygen
tension.
Pirbuterol acts as a vasodilator on the pulmonary
circulation in these patients and may in addition improve
right ventricular performance by an inotropic action.
Introduction
The association between the arterial hypoxaemia of chronic lung
diseases and the development of pulmonary hypertension is well
known,'-6 the hypoxaemia producing pulmonary vasocon-
striction by a mechanism as yet unknown. Although the pro-
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gression of pulmonary hypertension in patients with chronic
bronchitis and emphysema is slow,7 it heralds the development
of cor pulmonale, with a worsening of the prognosis.8 In these
patients with hypoxic cor pulmonale any drug that reduces
pulmonary artery pressure in the long term without further
disturbing the ventilation-perfusion balance should improve the
prognosis.
Pirbuterol is a beta sympathomimetic drug structurally
similar to salbutamol. Although animal studies in vitro have
shown its principal cardiovascular effect to be vasodilatation,9 in
vivo animal experiments have also shown it to have a positive
inotropic action.10 11 The distinction between these two actions
is difficult to establish in man; several studies, however, have
shown the beneficial effects of pirbuterol on the systemic circu-
lation both acutelyl2 13 and chronically"4 in ischaemic cardiac
failure.
We compared the acute haemodynamic effects of oral pir-
buterol with those of the vasodilator sodium nitroprusside
in patients with hypoxic chronic bronchitis and emphysema
with cor pulmonale. The chronic effects of oral pirbuterol were
assessed after six weeks' treatment with the drug. We combined
radionuclide ventriculography with pulmonary haemodynamic
measurements to obtain a detailed assessment of the effects of
pirbuterol on right ventricular performance.
Patients and methods
We studied 12 patients (six men, six women) aged 42-72 with
severe irreversible airflow obstruction as a result of chronic bronchitis
and emphysemal5 (forced expiratory volume in one second 0-65
(SD 0-2), forced vital capacity 1 75 (0 59)1). All had hypoxaemia
(arterial oxygen tension 7-28 (0 28) kPa (55 (2) mm Hg)), and most
had hypercapnia (arterial carbon dioxide tension 6-65 (0 80) kPa
(50 (6) mm Hg)) with a compensated respiratory acidosis (hydrogen
ion concentration 42 (4) nmol (ng)/l. All had peripheral oedema,
indicating that they had had cor pulmonale at some time in the past,
but all were in a stable state at the time of study as defined by a stable
body weight, stable forced expiratory volume in one second, and the
absence of acute respiratory infection or peripheral oedema for three
weeks before study. Arterial blood gas tensions were also stable for
this period.
ACUTE STUDIES
All patients were receiving inhaled beta2- sympathomimetics and
ipratropium and also diuretics. One patient was receiving digoxin. To
ensure a stable physical and haemodynamic state during the study no
drugs were given on the morning of study, each patient's normal drug
treatment being given on the preceding evening. The patients were
studied while semisupine in bed in the afternoon after a light lunch;
no premedication was given.
Haemodynamic measurements were made with the patient at rest;
during infusion of sodium nitroprusside; and at intervals of 30
minutes for two hours after oral pirbuterol was given. Ten of the 12
patients received intravenous sodium nitroprusside in a dose of
1-5 mg/kg body weight, which reduced systemic arterial blood pres-
sure by at least 10 mm Hg and mean pulmonary artery pressure by at
least 5 mm Hg. When all of the haemodynamic variables had returned
to control values pirbuterol was given by mouth in a dose of 22-5 mg
(six patients) or 15 mg (six patients).
CHRONIC STUDIES
Nine of the 12 patients who were studied acutely also then received
oral pirbuterol 15 mg three times a day in addition to their usual drugs
for six weeks, at which time pulmonary artery pressure and right and
left ventricular ejection fractions were measured. Three patients did
not complete this study: two developed an arrhythmia possibly
associated with pirbuterol, and one had an intercurrent infective
exacerbation of bronchitis at the time at which the six week study was
planned.
MEASUREMENTS
Arterial blood gas tensions when the patients breathed air were
measured during the control period, 90 minutes after pirbuterol was
given, and after six weeks' treatment. Ear oxygen saturation was
measured continuously during the acute study with a Hewlett-
Packard (47201A) ear oximeter. Heart rate was measured from the
electrocardiograph, and systemic arterial blood pressure with a
sphygmomanometer. Right atrial, right ventricular, and pulmonary
artery pressures were measured with a Swan-Ganz flow directed triple
lumen catheter. Measurements were averaged over five respiratory
cycles. All intracardiac pressures were referenced to a point 5 cm
below the sternal angle. Cardiac output was measured in triplicate by
thermodilution. As left atrial pressure is not always easy to assess from
pulmonary artery wedge pressure in these patients total pulmonary
vascular resistance was calculated by the formula:
Total pulmonary vascular resistance (kPa s/cm5)=
pulmonary artery pressure (mm Hg) X 8
cardiac output (1)
Right and left ventricular ejection fractions were measured by a
modified gated equilibrium blood pool radionuclide technique.'6
Briefly, after intravenous injection and equilibration in the blood
pool of human serum albumin labelled with 750 MBq technetium-99m
imaging is carried out in a 20° left anterior oblique position with a 100
caudal tilt. Left ventricular ejection fraction is calculated in the normal
manner, but for the right ventricle separate regions of interest at end
systole and end diastole must be identified. This is accomplished by a
combination of inspection of the ventriculogram, an edge detection
programme, and a Fourier based phase analysis. The method gives
values close to those obtained with the "single pass" technique, with
low inter observer and intra observer variation, and, moreover, allows
multiple ventriculograms to be obtained under different physiological
and pharmacological conditions.
End diastolic volumes were calculated from the following equations:
cardiac outputStroke volume= heart rate
fraction
end diastolic volume end systolic volume
end diastolic volume
stroke volume
end diastolic volume
Twelve minute walking distance"7 was measured in seven patients
before and after six weeks of treatment with oral pirbuterol.
In 10 patients pirbuterol concentrations were assayed in venous
plasma'8 one and two hours after the drug was given. Values are
expressed as means (SEM). Differences between means were compared
with a paired t test or with analysis of variance when repeated measure-
ments were made.
Results
ACUTE STUDY
The maximum effects of pirbuterol occurred 90 minutes after the
drug was given, and therefore we quote only these results. In the six
patients who received 22-5 mg pirbuterol neither sodium nitroprusside
nor pirbuterol significantly changed ear oxygen saturation or arterial
oxygen and carbon dioxide tensions (table I). Systemic arterial blood
pressure fell with sodium nitroprusside but was unaltered by pir-
buterol. Both drugs produced a small increase in heart rate of an
average of five beats/min. Sodium nitroprusside also reduced pul-
monary arterial pressure, by 2300, but had no significant effect on
cardiac output, whereas pirbuterol reduced pulmonary artery pressure
by 130 and increased cardiac output by 2100 and stroke volume by
900. Sodium nitroprusside and pirbuterol both reduced pulmonary
vascular resistance, but this was more noticeable with pirbuterol
(table 1). Both drugs reduced systemic vascular resistance by a
similar amount. Left ventricular ejection fraction rose with both
sodium nitroprusside and pirbuterol, but this increase was not
significant after pirbuterol. The greater increase in left ventricular
ejection fraction with sodium nitroprusside was associated with a
reduction in left ventricular end diastolic volume. In contrast, sodium
nitroprusside did not significantly change right ventricular ejection
fraction, whereas this rose with pirbuterol.
In the six patients given 15 mg pirbuterol the effects on arterial
blood gas tensions and haemodynamics were similar to those produced
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TABLE I-Mean (SEM) haemodynamic variables and arterial blood gas tensions
during infusion of sodium nitroprusside and 90 minutes after administration of
oral pirbuterol 22-5 mg (n= 6)
90 mins after
Sodium 22-5 mg oral
Control nitroprusside pirbuterol
Heart rate (beats/min) 89 (4) 95 (5)* 95 (4)*
Arterial blood pressure (mm Hg):
Systolic 126 (6) 99 (5)+ 123 (5)
Diastolic 75 (4) 58 (2)t 72 (5)
Arterial blood gas tensions (kPa):
Oxygen 7-0 (0-4) 6 6 (0-3)
Carbon dioxide 6-6 (0 2) 6-4 (0-3)
Oxygen saturation C,) 88 (1) 87 (2) 87 (2)
Hydrogen ion concentration (nmol/l) 41 (2) 41 (2)
Pulmonary artery pressure (mm Hg):
Systolic 48 (4) 35 (3)+ 40 (3)*
Diastolic 24 (2) 20 (2)t 23 (2)
Mean 31 (2) 24 (2)t 27 (2)
Cardiac output (1/min) 4 53 (0-26) 4-43 (0-18) 5-46 (0-24)t
Pulmonary vascular resistance (kPa s/cm5) 55-6 (5-3) 43-7 (5-3)t 40-7 (4-9)t
Right ventricular ejection fraction 0-45 (0-02) 0-48 (0 03) 0 54 (0-3)t
Left ventricular ejection fraction 0-61 (0-05) 0-71 (0-05)* 0-67 (0-05)
Stroke volume (ml) 52 (4) 48 (4) 58 (3)*
Right ventricular end diastolic
volume (ml) 114 (6) 100 (7) 112 (11)
Left ventricular end diastolic volume (ml) 87 (10) 79 (9)* 90 (9)
Significance of difference from control values: * p 0-05, t p<-001, $ p -0-001.
Con1version: SI to traditionzal units-Blood gas tensions: 1 kPaz7 5 mm Hg.
Pulmonary vascular resistance: 1 kPa s!l 0-1 dyne s/cmS.
by the higher dose of the drug, although the changes in pulmonary
artery pressure were no longer significant (table II). Two patients were
not given intravenous sodium nitroprusside during the acute study;
this did not alter the effects of oral pirbuterol given subsequently.
Plasma pirbuterol concentrations varied (table III), and we could
not establish a significant relation between the concentrations and any
of the haemodynamic variables. In the six patients given 22-5 mg
pirbuterol the plasma pirbuterol concentrations achieved a therapeutic
level, and in these six patients significant reductions in pulmonary
artery pressure were achieved. Lower plasma pirbuterol concentra-
tions occurred in the six patients given 15 mg pirbuterol, and in three
patients (cases 7, 8, 11) with very low concentrations pulmonary artery
pressure did not fall.
TABLE II-Mean (SEM) haemodynamic variables and arterial blood gas
tensions during infusion of sodium nitroprusside and 90 minutes after administra-
tion of oral pirbuterol 15 mg (n= 6)
90 mins after
Sodium 15 mg oral
Control nitroprusside pirbuterol
Heart rate(beats/min) 86 (7) 97 (12) 97 (8)*
Arterial blood pressure (mm Hg):
Systolic 122 (6) 101 (5)4 122 (6)
Diastolic 74 (6) 58 (3)t 74 (3)
Arterial blood gas tensions (kPa):
Oxygen 7 5 (0-2) 6-5 (0-4)
Carbon dioxide 6-7 (0-4) 6-2 (0-3)
Oxygen saturation (sO) 86 (1) 85 (3) 84 (3)
Hydrogen ion concentration (nmol/l) 43 (1) 44 (1)
Pulmonary artery pressure (mm Hg):
Systolic 46 (5) 37 (5)+ 48 (6)
Diastolic 22 (2) 18 (3)t 21 (2)
Mean 27 (3) 20 (3)t 28 (3)
Cardiac output (1/min) 4-34 (0 50) 4 59 (0-79) 5-66 (0 60)t
Pulmonary vascular resistance (kPa s/cm5) 51-1 (3-6) 37-6 (8-5) 39-2 (2-3)t
Right ventricular ejection fraction 0 47 (0-04) 0-55 (0-08) 0 53 (0-04)*
Left ventricular ejection fraction 0-56 (0-02) 0-61 (0-03)t 0-59 (0-03)
Stroke volume (ml) 52 (7) 49 (7) 61 (8)*
Right ventricular end diastolic
volume (ml) 117 (21) 91 (13)* 116 (14)
Left ventricular end diastolic volume (ml) 95 (14) 80 (13) 103 (13)
Significance of difference from control values: * p - 0-05, t p <0-01, + p<0-001.
Conversion: SI to traditional units-Blood gas tensions: 1 kPaz 7-5 mm Hg.
Pulmonary vascular resistance: 1 kPa s/l 0-1 dyne s/cmS.
CHRONIC STUDY
In the nine patients who were treated with pirbuterol for six weeks
systolic pulmonary artery pressure was reduced as compared with the
control values and the right ventricular ejection fraction was increased,
but there was no significant fall in arterial oxygen tension or signifi-
cant increase in heart rate (table IV). Forced expiratory volume in one
second, forced viral capacity, body weight, and 12 minute walking
distance were also unchanged over this period.
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TABLE iII-Plasma pirbuterol concentrations in 10 patients
60 and 120 minutes after administration of the drug
Plasma pirbuterol
Case No Dose of pirbuterol (g/1)(mg)
60 min 120 min
3 22 5 45-1 34-6
4 22 5 9-6 35-2
5 22-5 4-2 45-0
6 22-5 43-7 24-8
7 15 8-1 10-0
8 15 2.1 1 9
9 15 26-1 362
10 15 19-4 36-8
11 15 6-9 3 7
12 15 348 33-9
TABLE iv-Mean (SEM) haemodynamic variables and arterial blood gas
tensions before and after six weeks' treatment with oral pirbuterol 15 mg thrice
daily (n= 9)
After six weeks' pirbuterol
Control 15 mg thrice daily
Heart rate (beats/min) 86 (5) 92 (5)
Arterial blood pressure (mm Hg):
Systolic 124 (5) 121 (5)
Diastolic 73 (4) 74 (3)
Arterial blood gas tensions (kPa):
Oxygen 7-2 (0-3) 6-9 (0-2)
Carbon dioxide 6-8 (0-2) 7-2 (0-3)
Oxygen saturation (%) 86 (2) 84 (2)
Hydrogen ion concentration
(nmol/1) 43 (1) 44 (1)
Pulmonary artery pressure (mm Hg):
Systolic 43 (3) 35 (2)t
Mlean 28 (2) 26 (2)
Right ventricular ejection fraction 0-45 (0-04) 0-52 (0-03)t
Left ventricular ejection fraction 0-60 (0-03) 0-61 (0-03)
Forced expiratory volume in 1 s(l) 0-58 (0-06) 0-60 (0-05)
Forced vital capacity (1) 1-66 (0-1) 1 66 (0-1)
12 minute walking distance (m) 424 (100) 439 (104)
Significance of difference from control values: * p- 0-05, t p 0-01, + p<0-001.
Conversion: SI to traditional units-Blood gas tensions: 1 kPa z 7-5 mm Hg.
Discussion
We showed that modest reduction in systolic pulmonary
arterial pressure may be achieved with the beta agonist pirbuterol
in patients with pulmonary hypertension as a result of severe
hypoxic chronic bronchitis and emphysema. This effect was
sustained after six weeks of oral treatment with pirbuterol.
Moreover, cardiac output and right ventricular ejection fraction
increased in all patients, with both 15 and 22 5 mg pirbuterol.
Cardiac output rose principally as stroke volume increased.
Pulmonary vascular resistance fell, this reduction being greater
than with the vasodilator sodium nitroprusside. Pulmonary
vasodilatation was induced by pirbuterol with no change in
systemic blood pressure.
Pirbuterol increases cardiac output in patients with severe
congestive cardiac failure,12- s 19 but these effects, as in our
study, are not well correlated with plasma concentration.12 In
our study the maximum effects of pirbuterol occurred at 90
minutes.
Debate continues over whether the mechanism of these
haemodynamic effects of pirbuterol is inotropic or simply
secondary to the vasodilator properties.'2 a9 20 In this study
vasodilatation by sodium nitroprusside produced a fall in
pulmonary artery pressure but no change in cardiac output,
whereas pirbuterol produced a fall in pulmonary artery pressure
and an increase in cardiac output. Arguably, sodium nitro-
prusside is not the ideal vasodilator to be contrasted with
pirbuterol because of its combined arterial and venous effects.
The comparison may, however, be valid as pirbuterol is also
thought to have venodilator properties.21 Assessment of con-
tractility in man is difficult. Ventricular ejection fractions and
other variables of the ejection phase are influenced by alterations
in the loading conditions of the ventricles, and in particular by
changes in the afterload. Sagawa et al suggested that the relation
of the end systolic pressure to the end systolic volume is not
influenced by the loading conditions of the ventricle but is
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sensitive to inotropic interventions.22 We drew idealised loops of
right ventricular pressure and volume when the pressure
changes were greatest for the six patients given 22-5 mg pir-
buterol (figure). The pressure and volumes at end systole and
end diastole were measured; others were not. Sodium nitro-
prusside displaces the end systolic pressure volume point
downwards. If pirbuterol was acting only as a vasodilator
the relation between the two variables would fall on the same
line, but after pirbuterol this point is displaced leftwards,
implying that pirbuterol has an additional inotropic action.
The beta agonist terbutaline usually has effects on pulmonary
artery pressure, cardiac output, and pulmonary vascular resist-
60 Control
5)
uD 50- 'trLnnitroprusside
Pirbuterol A -
a 20-
10
0
10 20 30 40 50 60 70 80 90 100 110 120 130
Right ventricular volume (ml)
Pressure volume loops from right ventricles in six patients with chronic
bronchitis and emphysema during control conditions ( 0), during infusion
of sodium nitroprusside ( *), and after administration of pirbuterol 22-5 mg
(A). Points shown are mean end diastolic (on the right) and mean end
systolic (on the left) pressure volume points.
ance similar to those of pirbuterol,2' at least when given either
intravenously24 or subcutaneously,25 but the effects of oral dosing
are unknown.
As pirbuterol produced only modest reductions in pulmonary
artery pressure, the fall in pulmonary vascular resistance was
largely due to an increase in cardiac output, which occurred in
all patients. However, no significant further fall in arterial oxygen
saturation occurred in these patients as a result of the haemo-
dynamic effects of pirbuterol. This is in contrast to results of
previous studies in patients with acute bronchial asthma, in
which both aminophylline26 and non-selective adrenergic
agents27 reduced arterial oxygen saturation despite improving
airway resistance. A recent study, however showed that the
beta2- agonist terbutaline when given intravenously did not
change venous admixture or arterial oxygen tension in patients
with chronic bronchitis and emphysema.
The reductions in pulmonary artery pressure produced by
acute administration of pirbuterol were sustained after six weeks'
oral treatment. Side effects of pirbuterol were few, but multiple
ventricular ectopic beats occurred in one patient during the
acute study after 22-5 mg pirbuterol, and atrial fibrillation
occurred in another patient during the chronic study. Both had
had frequent ventricular and supraventricular ectopic beats
before starting the drug. Five further patients showed no
increase in the number of ectopic beats during 24 hour ambula-
tory cardiac monitoring during the chronic study. We suggest,
however, that pirbuterol is contraindicated in patients with
frequent ectopic beats, as has been recommended by others.2'
These initial results in a group of severely disabled patients
suggest that pirbuterol may be valuable in patients with the
"blue and bloated" syndrome of chronic bronchitis and
emphysema because it vasodilates the pulmonary circulation, so
improving right ventricular performance and thus systemic
oxygen delivery, and does not aggravate hypoxaemia. Whether
these haemodynamic benefits, if produced by pirbuterol over the
long term, will improve the grave outlook for such patients
remains to be determined, as also does the role of pirbuterol
given in addition to long term continuous oxygen treatment in
such patients.30 31
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